Concerned about FDA secondary cancer warnings when using Revlimid?
Dr. Berenson also comments on a new study from Sweden regarding increased risk of blood clots among myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference in Chicago during the first week of June.
Click on the headline link below to access Mr. Schorr’s site–and watch his video interview with Dr. Berenson:
Understanding Myeloma News About Secondary Cancers and Clotting
My advice to patients and caregivers concerned about secondary cancer risks from using Revlimid: Take a step-back and give all of this time to play-out.
If you read any of the comments following my report about the new FDA secondary cancer warning,
BREAKING NEWS: FDA warns of significant secondary cancer risk from using Revlimid.
You would have immediately sensed that fellow myeloma patients aren’t overly concerned about the news. I think that Mark summed it up best when he wrote:
“I agree with Justin S that Revlimid is a “necessary evil” given the lack of therapy options available to most myeloma patients currently. Just as an observation, it seems a lot of the side effects that occur in Myeloma patients are because of the “new paradigm” of continuous treatment with Revlimid.”
Mark makes a great point about “continuous treatment.” Four or five years ago, patients would take a “drug holiday” after using Revlimid, Thalomid or Velcade long enough to knock their myeloma back. Then, if and when their myeloma returned, treatment would resume.
These days, treatment is more likely to be continual–like my “RVD light” maintenance regimen.
I will be addressing this new therapy trend in an upcoming post. Maybe it’s time to take a step-back and consider taking a drug holiday if and when your multiple myeloma is under control?
Feel good and keep smiling! Pat
Hiç yorum yok:
Yorum Gönder